BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
To ensure personalised treatment for familial hypercholesterolemia
To develop relevant 3D models of different tumors, in order to better assess the efficiency of anticancer therapies.
A holistic approach to address brain delivery
Face to the high failure of drug candidate in clinical trial, in particular involving the brain, we goal to develop more relevant and more predictive in vitro models for preclinical assessment, in the aim to early select molecules of interest, in term of efficacy and safety.
To design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D
To develop the technological platform to produce lab-grown meats. The project is funded by EUREKA and the national funding agencies associated with the Eurostars program.
To develop a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid in order to predict the hepatoxicity of drugs.
To explore the use of AI technologies to improve different steps of 3D biological picture exploitation
Have you missed our last webinar with Molecular Devices about 3D oncology models? In April, our project leader Elodie was talking about how to establish and image physiologically relevant 3D cancer in vitro models, using Read more…
Since the beginning of this year we have created four webinars to present our BIOMIMESYS® technology and practical uses. We have chosen to focus on the scientific side of our innovation by presenting results in Read more…
Pharmaceutical industry is facing a very high failure rate in drug discovery, with 90% of failure in clinical trials. This is particularly true for central nervous system applications, with a rate of 30% safety failure Read more…
Maybe you are looking for a solution for your 3D cell culture and, after a Google or a Pubmed search, you find us and the BIOMIMESYS® technology. Or, you saw a publication or a poster Read more…
Please feel free to follow us in these conferences: on Thursday 27th, we will attend the virtual Joint Meeting of the French and German Societies for Matrix Biology. Let’s talk about BIOMIMESYS technology (poster n°105, Read more…
The annual congress of the SCMC (Societé Cerveau et Maldies Cérébraux Vasculaires – Brain and cerebrovascular diseases Society) will take place this Friday, may 28 2021 (virtual congress). On this occasion, our PhD student Véronique Read more…
We have a new arrival in our laboratory! As part of her diploma “DUT Génie Biologique”, specialized in biological and biochemistry analysis, Laura has joined us for a four months’ internship in dermocosmetology, in order Read more…
Ask for high quality link by putting your email below There is a 90% failure in clinical trials, due to efficacy and safety issues, which frequently concerns the central nervous system. That points a lack Read more…
Raising funds in Europe when we carry a disruptive technology such as BIOMIMESYS technology which requires substantial financial investment for R&D is not so easy. Fortunately, Europe has understood this well and is helping entrepreneurs Read more…
We are very please to welcome two new members in our scientific advisory board. Dr Vincent Senez from the Institute of Cancer Research of Lille (IRCL) is specialized in microfluidics and lab-on-a-chip technologies. We work Read more…
The international NeuroFrance congress will take place May, 19, 20 and 21th 2021 (virtual meeting). On this occasion, our PhD student Véronique De Conto will present these works in a poster about the importance of Read more…
The pharmaceutical industries face to a major issue, which is a very high failure rate in drug discovery, with 90% of failure in clinical trials. The central nervous system is particularly concerned, with an involvement Read more…
If you want to better known what we are doing now in HCS Pharma and if your native language is korean, you can discover it with this article : HCS Pharma, 생리학적으로 중요한 3d Cell Read more…
When Tuesday, June 1, 2021 – 1PM (CET) / 8PM (CST) / 9PM (JST) / 7AM (EST) Thursday, June 3, 2021 – 9AM (CET) / 4PM (CST) / 5PM (JST) / 3AM (EST) Where Online, using zoom.us Read more…
Our entire product range BIOMIMESYS® is now available in the new catalogue 2021 of Dominique Dutscher company. You can find it in the paper one but also in the “cell culture” e-catalogue on page 7 Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.